<DOC>
	<DOCNO>NCT00006929</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine suramin , paclitaxel , carboplatin treat patient stage IIIB stage IV non-small cell lung cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Suramin , Paclitaxel , Carboplatin Treating Patients With Stage IIIB Stage IV Non-small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine minimum effective dose suramin reduce resistance chemotherapy paclitaxel carboplatin patient stage IIIB IV non-small cell lung cancer ( phase I ) . ( Phase I close accrual 1/29/02 ) . II . Evaluate pharmacokinetic interaction drug combination patient ( phase I ) . ( Phase I close accrual 1/29/02 ) . III . Determine objective response rate patient treat regimen ( phase II [ chemotherapy-naive patient close accrual 9/1/03 ] ) . IV . Determine time tumor progression , progression-free rate 6 month , 1-year survival patient treat regimen ( phase II [ chemotherapy-naive patient close accrual 9/1/03 ] ) . OUTLINE : Patients phase II stratify accord prior treatment ( chemotherapy naive [ close accrual 9/1/03 ] v chemotherapy refractory ) . Phase I ( phase I close accrual 1/29/02 ) : Patients receive suramin IV 30 minute day 1 2 . Patients also receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos suramin target dose determine . The target dose define dose least 5 6 patient achieve optimal plasma concentration suramin 1 6 patient exceed optimal level . Doses paclitaxel adjust maximum tolerate dose combination suramin paclitaxel determine . Phase II ( chemotherapy-naive patient close accrual 9/1/03 ) : Patients receive target dose suramin IV 30 minute day 1 2 . Patients also receive paclitaxel IV 3 hour carboplatin IV 1 hour day 1 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 3-6 week . PROJECTED ACCRUAL : Approximately 82 patient ( 18 phase I [ phase I close accrual 1/29/02 ] 64 phase II [ chemotherapy-naive patient close accrual 9/1/03 ] ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Suramin</mesh_term>
	<criteria>Histologically cytologically confirm advanced nonsmall cell lung cancer Stage IIIB amenable concurrent chemotherapy radiotherapy ( e.g. , pleural effusion low pulmonary reserve ) Stage IV Measurable disease Meets criteria 1 following : Chemotherapy naive ( phase I II ) ( phase I close accrual 1/29/02 ) ( phase II [ chemotherapynaive patient ] close accrual 9/1/03 ) Previously treat ( phase I ) ( phase I close accrual 1/29/02 ) Received 1 prior chemotherapy regimen Chemotherapy refractory , define disease progression within 3 month carboplatin/paclitaxel chemotherapy ( phase II ) No know brain leptomeningeal disease unless previously irradiate , currently undergo corticosteroid therapy , clinically asymptomatic Performance status ECOG 02 At least 12 week Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 9.0 g/dL Platelet count least 100,000/mm^3 Bilirubin great 1.5 mg/dL AST ALT great 2.5 time upper limit normal Creatinine great 1.5 mg/dL Creatinine clearance least 50 mL/min Calcium le 11.5 mg/dL No history myocardial infarction within past 6 month No history congestive heart failure require therapy No history unstable angina Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No active serious infection HIV negative No concurrent uncontrolled diabetes mellitus No known hypersensitivity Cremophor EL No grade 2 great neuropathy No malignancy within past 5 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No known psychiatric condition would preclude study compliance At least 28 day since prior cytotoxic chemotherapy recover Prior radiotherapy allow except indicator lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>